Search

Author/Creator Baron, Ari D.

1. Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17–25]. (September 2018)

Authors:
Chau, Ian; Peck-Radosavljevic, Markus; Borg, Christophe; Malfertheiner, Peter; Seitz, Jean Francois; Park, Joon Oh; Ryoo, Baek-Yeol; Yen, Chia-Jui; Kudo, Masatoshi; Poon, Ronnie; Pastorelli, Davide; Blanc, Jean-Frederic; Chung, Hyun Cheol; Baron, Ari D.; Okusaka, Takuji; Bowman, L.; Cui, Zhanglin...
Journal:
European journal of cancer
Issue:
Volume 100(2018)
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. (11th August 2017)

Authors:
Patt, Yehuda Z.; Murad, Waheed; Fekrazad, Mohammed H.; Baron, Ari D.; Bansal, Pranshu; Boumber, Yanis; Steinberg, Kim; Lee, Sang‐Joon; Bedrick, Ed; Du, Ruofei; Lee, Fa Chyi
Journal:
Cancer medicine
Issue:
Volume 6:Number 9(2017:Sep.)
Page Start:
2042
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. (June 2022)

Authors:
Freemantle, Nick; Mollon, Patrick; Meyer, Tim; Cheng, Ann-Lii; El-Khoueiry, Anthony B.; Kelley, Robin K.; Baron, Ari D.; Benzaghou, Fawzi; Mangeshkar, Milan; Abou-Alfa, Ghassan K.
Journal:
European journal of cancer
Issue:
Volume 168(2022)
Page Start:
91
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. (August 2017)

Authors:
Chau, Ian; Peck-Radosavljevic, Markus; Borg, Christophe; Malfertheiner, Peter; Seitz, Jean Francois; Park, Joon Oh; Ryoo, Baek-Yeol; Yen, Chia-Jui; Kudo, Masatoshi; Poon, Ronnie; Pastorelli, Davide; Blanc, Jean-Frederic; Chung, Hyun Cheol; Baron, Ari D.; Okusaka, Takuji; Bowman, L.; Cui, Zhanglin...
Journal:
European journal of cancer
Issue:
Volume 81(2017)
Page Start:
17
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. (May 2020)

Authors:
Kim, Richard D.; McDonough, Shannon; El-Khoueiry, Anthony B.; Bekaii-Saab, Tanios S.; Stein, Stacey M.; Sahai, Vaibhav; Keogh, George P.; Kim, Edward J.; Baron, Ari D.; Siegel, Abby B.; Barzi, Afsaneh; Guthrie, Katherine A.; Javle, Milind; Hochster, Howard
Journal:
European journal of cancer
Issue:
Volume 130(2020)
Page Start:
219
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗